Xilis

Website

Xilis, Inc.

9 Investors
Biotechnology and Oncology
DURHAM, NC

Xilis, Inc. is a biotech company focused on transforming cancer treatment through innovative technologies that enable personalized medicine. By leveraging its proprietary MicroOrganoSphere™ technology, Xilis offers tailored therapeutic solutions that match cancer patients with the most effective treatments based on their individual tumor biology.

Products & Team

MicroOrganoSphere™ (MOS) Technology

Precision OncologySeed

The MicroOrganoSphere™ (MOS) technology allows the creation of miniature tumor models that preserve the critical biological characteristics of the original tumor. These microscale tumors enable clinicians to test various cancer therapies to determine which are most effective for individual patients.

Value Proposition

Xilis solves the challenge of generalized cancer treatments by providing personalized therapy recommendations that are based on the unique biology of each patient's tumor, thereby enhancing treatment efficacy.

Pain Points

Traditional cancer treatments often fail to account for individual variability in tumor biology, leading to ineffective therapies for patients.

Retains structure and genetic alterations of original tumorsPredicts drug response based on patient-specific biologyFacilitates high-throughput drug candidate screening
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
DURHAM, NC
Primary headquarters

Funding History

Total Raised:
$19.4M
E

Equity, Debt Financing Offering

Closed
April 2025
$19.4M
Raised
Progress
100%
Raised
$19.4M
Target
$19.4M
#000123191925000033